[Abstract Only] Randomized Trial: GLP-1 Receptor Agonist and Cardiovascular Outcomes in Type 2 Diabetes

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial – The Lancet (link to abstract – $ for full-text)

Commentary: Dulaglutide Cuts Cardiovascular Risk in Type 2 Diabetes – NEJM Journal Watch (free)

During a median follow-up of 5.4 years, the primary outcome (a composite endpoint of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes) occurred in 12.0% of participants in the dulaglutide group and in 13.4% of participants in the placebo group (incidence rate of 2.4 per 100 person-years vs 2.7 per 100 person-years in the placebo group).